ReviewTherapeutic advances in drug safety2017
Pegloticase in gout treatment - safety issues, latest evidence and clinical considerations.
Review in Therapeutic advances in drug safety, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Safety, Tolerability, and Efficacy of Shorter Infusion Durations of Pegloticase Administered to Patients With Uncontrolled Gout Receiving Methotrexate: AGILE Trial.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2026Trial
- Reducing Immunogenicity of Pegloticase With Concomitant Use of Mycophenolate Mofetil in Patients With Refractory Gout: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2021Trial
- First case report of hypouricemia associated with adjuvant imatinib therapy in a patient with small intestinal gastrointestinal stromal tumor.Frontiers in oncology · 2026Article
- The Role of Fast Blood Glucose to Albumin Ratio in Predicting Gout Relief Among Patients With Acute Gout Attack.International journal of endocrinology · 2026Article
- Article
- Evaluation of Real-World Treatment Patterns and Healthcare Resource Utilization in Patients with Chronic Refractory Gout in the United States.Advances in therapy · 2025Article
- Drug-Induced Hypouricemia.Drug safety · 2025Review
- Dissecting Uricase Immunogenicity: Unveiling the Role of Quaternary Epitopes through In Silico Analysis : Quaternary Epitope Insights in Uricase Immunogenicity.Galen medical journal · 2025Article
- Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy.Arthritis care & research · 2024Article
- A Review for Uncovering the "Protein-Nanoparticle Alliance": Implications of the Protein Corona for Biomedical Applications.Nanomaterials (Basel, Switzerland) · 2024Review
- Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation.Arthritis research & therapy · 2024Article
- PEGylated therapeutics in the clinic.Bioengineering & translational medicine · 2024Review
- Timely Shaver Treatment Removes Chronic Tophaceous Mass Improve Surgical Outcomes.International journal of medical sciences · 2024Article
- Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat.Cureus · 2023Review
- Randomized, Double-Blind, Placebo-Controlled, Phase I, Dose- Escalation Study to Evaluate the Tolerance, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PEGylated Urate Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers: Study Protocol.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Articular mobilization promotes improvement in functional and inflammatory parameters in a gouty arthritis model.Einstein (Sao Paulo, Brazil) · 2023Article
- Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme.Nature catalysis · 2022Article
- Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.Nature communications · 2022Article
- The past, present, and future of enzyme-based therapies.Drug discovery today · 2022Review
- High MW polyethylene glycol prolongs circulation of pegloticase in mice with anti-PEG antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gout is a common rheumatic condition, with increasing prevalence in recent decades. The mainstay of treatment for gout is oral urate-lowering therapy (ULT), typically with xanthine oxidase inhibitors (XOIs). Unfortunately, a proportion of patients have persistent gout that is refractory to ULT. Pegloticase, a recombinant pegylated uricase, has been approved by the US Food and Drug Administration for the treatment of refractory gout. However, concern has been raised regarding the risk of infusion reactions, which are now understood to be largely due to the development of antipegloticase antibodies. Discontinuation of pegloticase upon failure to lower serum urate has been shown to markedly reduce infusion reaction risk, but deprives patients of what, in many cases, is a last-resort treatment. In this manuscript, we review the rationale, mechanism of action, efficacy and safety of pegloticase. Additionally, we focus on potential strategies to reduce pegloticase immunogenicity and potentially make this important agent available to a wider group of patients requiring treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.